# Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

> **NCT05215574** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **NGM Biopharmaceuticals, Inc** · enrollment: 130 (estimated)

## Conditions studied

- Pancreatic Cancer
- Breast Cancer
- Gastric Cancer
- Non-small Cell Lung Cancer
- Cervical Cancer
- Endocervical Cancer
- Squamous Cell Carcinoma of Head and Neck
- Bladder Urothelial Cancer
- Colorectal Carcinoma
- Esophageal Cancer
- Ovarian Cancer
- Renal Cell Carcinoma
- Prostate Cancer
- Melanoma
- Mesothelioma
- Cholangiocarcinoma

## Interventions

- **DRUG:** NGM831
- **DRUG:** NGM831 plus pembrolizumab (KEYTRUDA®)
- **DRUG:** NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)

## Key facts

- **NCT ID:** NCT05215574
- **Lead sponsor:** NGM Biopharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-31
- **Primary completion:** 2025-07
- **Final completion:** 2026-03
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2024-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05215574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05215574, "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05215574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*